Journal of Diagnostics Concepts & Practice ›› 2021, Vol. 20 ›› Issue (01): 1-7.doi: 10.16150/j.1671-2870.2021.01.001
• Experts forum • Next Articles
Received:2020-02-10
Online:2021-02-25
Published:2022-06-28
CLC Number:
| [1] | 郑捷. 皮肤红斑狼疮的分型与诊断[J]. 诊断学理论与实践, 2004, 3(3):228-230. |
| [2] |
Jarukitsopa S, Hoganson DD, Crowson CS, et al. Epidemiology of systemic lupus erythematosus and cutaneous lupus erythematosus in a predominantly white population in the United States[J]. Arthritis Care Res (Hoboken), 2015, 67(6):817-828.
doi: 10.1002/acr.22502 pmid: 25369985 |
| [3] |
Sestak AL, Fürnrohr BG, Harley JB, et al. The genetics of systemic lupus erythematosus and implications for targeted therapy[J]. Ann Rheum Dis, 2011, 70(Suppl 1):i37-i43.
doi: 10.1136/ard.2010.138057 URL |
| [4] |
Peschke K, Friebe F, Zimmermann N, et al. Deregulated type I IFN response in TREX1-associated familial chilblain lupus[J]. J Invest Dermatol, 2014, 134(5):1456-1459.
doi: S0022-202X(15)36768-3 pmid: 24270665 |
| [5] |
Kim-Howard X, Maiti AK, Anaya JM, et al. ITGAM co-ding variant (rs1143679) influences the risk of renal di-sease, discoid rash and immunological manifestations in patients with systemic lupus erythematosus with European ancestry[J]. Ann Rheum Dis, 2010, 69(7):1329-1332.
doi: 10.1136/ard.2009.120543 pmid: 19939855 |
| [6] | Ceccarelli F, Perricone C, Borgiani P, et al. Genetic Factors in systemic lupus erythematosus: contribution to di-sease phenotype[J]. J Immunol Res, 2015, 2015:745647. |
| [7] |
Foering K, Chang AY, Piette EW, et al. Characterization of clinical photosensitivity in cutaneous lupus erythematosus[J]. J Am Acad Dermatol, 2013, 69(2):205-213.
doi: 10.1016/j.jaad.2013.03.015 URL |
| [8] |
Patsinakidis N, Wenzel J, Landmann A, et al. Suppression of UV-induced damage by a liposomal sunscreen: a prospective, open-label study in patients with cutaneous lupus erythematosus and healthy controls[J]. Exp Dermatol, 2012, 21(12):958-961.
doi: 10.1111/exd.12035 pmid: 23171460 |
| [9] |
Gehrke N, Mertens C, Zillinger T, et al. Oxidative da-mage of DNA confers resistance to cytosolic nuclease TREX1 degradation and potentiates STING-dependent immune sensing[J]. Immunity, 2013, 39(3):482-495.
doi: 10.1016/j.immuni.2013.08.004 URL |
| [10] |
Kaczmarczyk-Sekuła K, Dyduch G, Kostański M, et al. Mast cells in systemic and cutaneous lupus erythematosus[J]. Pol J Pathol, 2015, 66(4):397-402.
pmid: 27003772 |
| [11] |
Hersh AO, Arkin LM, Prahalad S. Immunogenetics of cutaneous lupus erythematosus[J]. Curr Opin Pediatr, 2016, 28(4):470-475.
doi: 10.1097/MOP.0000000000000383 URL |
| [12] |
Katayama S, Panelius J, Koskenmies S, et al. Delineating the Healthy Human Skin UV Response and Early Induction of Interferon Pathway in Cutaneous Lupus Erythematosus[J]. J Invest Dermatol, 2019, 139(9):2058-2061.
doi: 10.1016/j.jid.2019.02.035 URL |
| [13] |
Biazar C, Sigges J, Patsinakidis N, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE)[J]. Autoimmun Rev, 2013, 12(3):444-454.
doi: 10.1016/j.autrev.2012.08.019 pmid: 23000206 |
| [14] |
Norman R, Greenberg RG, Jackson JM. Case reports of etanercept in inflammatory dermatoses[J]. J Am Acad Dermatol, 2006, 54(3 Suppl 2):S139-S142.
doi: 10.1016/j.jaad.2005.11.1090 URL |
| [15] |
Li PH, Wong WH, Lee TL, et al. Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese[J]. Rheumatology (Oxford), 2013, 52(2):337-345.
doi: 10.1093/rheumatology/kes261 URL |
| [16] |
Klein R, Moghadam-Kia S, LoMonico J, et al. Development of the CLASI as a tool to measure disease severity and responsiveness to therapy in cutaneous lupus erythematosus[J]. Arch Dermatol, 2011, 147(2):203-208.
doi: 10.1001/archdermatol.2010.435 URL |
| [17] |
Albrecht J, Taylor L, Berlin JA, et al. Index): an outcome instrument for cutaneous lupus erythematosus[J]. J Invest Dermatol, 2005, 125(5):889-894.
pmid: 16297185 |
| [18] |
Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies[J]. Nat Rev Rheumatol, 2019, 15(9):519-532.
doi: 10.1038/s41584-019-0272-0 pmid: 31399711 |
| [19] | 中华医学会皮肤性病学分会红斑狼疮研究中心. 皮肤型红斑狼疮诊疗指南(2019版)[J]. 中华皮肤科杂志, 2019, 52(3):149-155. |
| [20] |
Zahn S, Graef M, Patsinakidis N, et al. Ultraviolet light protection by a sunscreen prevents interferon-driven skin inflammation in cutaneous lupus erythematosus[J]. Exp Dermatol, 2014, 23(7):516-518.
doi: 10.1111/exd.12428 URL |
| [21] |
Pindado-Ortega C, Alegre-Sánchez A, Pérez-García B, et al. Reply to: S2k guideline for treatment of cutaneous lupus erythematosus-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology(EADV)[J]. J Eur Acad Dermatol Venereol, 2019, 33(2):e70-e71.
doi: 10.1111/jdv.15209 |
| [22] |
Kuznik A, Bencina M, Svajger U, et al. Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines[J]. J Immunol, 2011, 186(8):4794-4804.
doi: 10.4049/jimmunol.1000702 URL |
| [23] |
Yokogawa N, Eto H, Tanikawa A, et al. Effects of hydroxychloroquine in patients with cutaneous lupus Erythematosus: a Multicenter, double-blind, randomized, parallel-group trial[J]. Arthritis Rheumatol, 2017, 69(4):791-799.
doi: 10.1002/art.40018 URL |
| [24] |
Sakthiswary R, Suresh E. Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy[J]. Lupus, 2014, 23(3):225-235.
doi: 10.1177/0961203313519159 pmid: 24399812 |
| [25] |
Felten R, Dervovic E, Chasset F, et al. The 2018 pipeline of targeted therapies under clinical development for systemic lupus erythematosus: a systematic review of trials[J]. Autoimmun Rev, 2018, 17(8):781-790.
doi: 10.1016/j.autrev.2018.02.011 URL |
| [26] |
Klebes M, Wutte N, Aberer E. Dapsone as second-line treatment for cutaneous lupus erythematosus? a retrospective analysis of 34 patients and a review of the literature[J]. Dermatology, 2016, 232(1):91-96.
doi: 10.1159/000441054 URL |
| [27] |
Thomas S, Fisher KH, Snowden JA, et al. Methotrexate is a JAK/STAT pathway inhibitor[J]. PLoS One, 2015, 10(7):e0130078.
doi: 10.1371/journal.pone.0130078 URL |
| [28] | Goldacre B, DeVito NJ, Heneghan C, et al. Compliance with requirement to report results on the EU Clinical Trials Register: cohort study and web resource[J]. BMJ, 2018, 362:k3218. |
| [29] |
Hofmann SC, Leandro MJ, Morris SD, et al. Effects of rituximab-based B-cell depletion therapy on skin manifestations of lupus erythematosus--report of 17 cases and review of the literature[J]. Lupus, 2013, 22(9):932-939.
doi: 10.1177/0961203313497115 pmid: 23894047 |
| [30] |
Biliouris K, Nestorov I, Naik H, et al. A pre-clinical quantitative model predicts the pharmacokinetics/pharmacodynamics of an anti-BDCA2 monoclonal antibody in humans[J]. J Pharmacokinet Pharmacodyn, 2018, 45(6):817-827.
doi: 10.1007/s10928-018-9609-6 URL |
| [31] |
Wenzel J, van Holt N, Maier J, et al. Wolf D. JAK1/2 inhibitor ruxolitinib controls a case of chilblain lupus erythematosus[J]. J Invest Dermatol, 2016, 136(6):1281-1283.
doi: S0022-202X(16)00500-5 pmid: 26916391 |
| [32] |
Aringer M, Smolen JS. Efficacy and safety of TNF-blocker therapy in systemic lupus erythematosus[J]. Expert Opin Drug Saf, 2008, 7(4):411-419.
doi: 10.1517/14740338.7.4.411 pmid: 18613805 |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
